Compare Recursion Pharmaceuticals Inc (RXRX) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TJX Companies Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.26 (market cap $2.14B), while TJX Companies Inc trades at $139.03 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 71.3× Recursion Pharmaceuticals Inc's market cap, and TJX Companies Inc pays a 1.38% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and TJX Companies Inc for 97 Days on average.
| RXRX | TJX | |
|---|---|---|
Market Cap | $2.14B | $152.62B |
Volume | 30,789,535 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $168.41 |
52-Week Low | $2.84 | $122.84 |
Typical Hold Time | 23 Days | 97 Days |
Enterprise Value | $1.66B | $160.93B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
TJX trades at $138.70, down slightly by 0.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings near 75. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $56.36 billion and $4.86 billion in 2025, respectively, while maintaining a robust ROE of 62.17%.
Wall Street analysts are overwhelmingly bullish, with an 84.9% buy rating and a consensus price target of $174.15, implying 28% upside. Key risks include competitive pressures in off-price retail and potential macroeconomic headwinds affecting consumer spending. The stock's valuation at a P/E of 25.69 appears justified by its earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
